FDA Enforcement Actions Against False and Misleading Prescription Drug Advertisements Declined in 2003
Loading...
Serial Number
Levin Center Identifier
Document Date
2004-01-29
Report Length
8 pages
Policy Agendas Project Major Code
Policy Agendas Project Minor Code
Additional, Minority, Dissenting Views
Report Type
Found Using Methodology
Yes
Committee(s)
Subcommittee(s)
Commission(s)
Idependent Author(s)
Brief Executive Summary
The Special Investigations Division of the House Committee on Government Reform investigated a significant drop in FDA enforcement actions against false and misleading drug advertising during the first two years of the Bush Administration. Despite FDA Commissioner Mark McClellan's promise of more aggressive enforcement in 2003, the report states enforcement actions continued to decline that year, and delays in responding to false and misleading advertisements increased. The division suggest a contrast between the Commissioner's commitment and the actual enforcement trends at the FDA.